EyeGate Pharma's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis
4/9/2013 11:40:38 AM
More...
|
EyeGate Pharma Enrolls Last Patient in Pivotal Phase III Anterior Uveitis Study of EGP-437
12/18/2012 8:45:33 AM
More...
|
EyeGate Pharma Initiates Phase III Study of EGP-437 in Patients With Anterior Uveitis
1/5/2012 9:06:00 AM
More...
|
EyeGate Pharma Secures Additional $5.9M Series D Venture Funding
1/5/2011 6:42:21 AM
More...
|
EyeGate Pharma Awarded Grants Totaling Nearly $1 Million by United States Government Section 48D Therapeutic Discovery Program
11/4/2010 9:15:13 AM
More...
|
RXi Pharmaceuticals (RXII) and EyeGate Pharma Announce Collaboration Focused on Non-Invasive Ocular Delivery of RNAi Therapeutics
9/22/2010 9:56:16 AM
More...
|
EyeGate Pharma Initiates ALLUVION Phase III Study of EGP-437 in Patients With Dry Eye Syndrome
6/24/2010 8:41:15 AM
More...
|
EyeGate Pharma Establishes Research Collaboration With GlaxoSmithKline (GSK) to Deliver Medicines Using the EyeGate(R) II Delivery System
4/29/2010 11:20:47 AM
More...
|
EyeGate Pharma Completes Phase II Study of EGP-437 in Patients With Anterior Uveitis
3/25/2010 11:04:58 AM
More...
|
EyeGate Pharma Secures $22M in Series D Venture Funding for Continued Development of EGP-437 for Dry Eye Syndrome
1/8/2010 7:05:10 AM
More...
|
|